Abstract
We present a case of the successful use of bosentan for increased pulmonary vascular resistance (PVR) in a 10-year-old male who underwent late single ventricle surgical palliation for double-inlet left ventricle with pulmonary artery banding and a bidirectional Glenn shunt. The patient was treated with bosentan for 16 weeks, with decreases in mean pulmonary artery pressure from 23 to 16 mmHg on the right and from 31 to 21 mmHg on the left, and a decrease of the transpulmonary gradient by 7–8 mmHg. Cardiopulmonary exercise testing demonstrated an increase in peak oxygen consumption (VO2) by 8% and peak work rate by 10%. Bosentan is a relatively new oral therapy option for increased PVR in patients with single ventricle physiology and bidirectional Glenn shunts.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alejos JC, Williams RG, Jarmakani JM, et al. (1995) Factors influencing survival in patients undergoing the bidirectional Glenn anastamosis. Am J Cardiol 75:1048–1050
Fratz S, Geiger R, Kresse H, et al. (2003) Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg 126:1724–1729
Galie N, Beghetti M, Gatzoulis MA, et al. (2006) Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114:48–54
Granton JT, Rabinovitch M (2002) Pulmonary arterial hypertension in congenital heart disease. Cardiol Clin 20:441–457, vii
Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B (1999) Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med 37:423–428
Maiya S, Hislop AA, Flynn Y, Haworth SG (2006) Response to bosentan in children with pulmonary hypertension 92:664–670
Mayer JE (2006) Surgical management of the patient with the univentricular heart. In: Keane JF, Lock JE, Fyler DC (eds.) Nadas’ Pediatric Cardiology, 2nd ed. Saunders, Philadelphia, pp 863–868
Pridjian AK, Mendelsohn AM, Lupinetti FM, et al. (1993) Usefulness of the bidirectional Glenn procedure as a staged reconstruction for the functional single ventricle. Am J Cardiol 71:959–962
Rosenzweig EB, Ivy DD, Widlitz A, et al. (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46:697–704
Sitbon O, Beghetti M, Petit J, et al. (2006) Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 36(Suppl 3):25–31
Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW (1993) Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood blow. Am J Cardiol 71:1204–1207
Yoshibayashi M, Nishioka K, Nakao K, et al. (1991) Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation 84:2280–2285
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Votava-Smith, J.K., Perens, G.S. & Alejos, J.C. Bosentan for Increased Pulmonary Vascular Resistance in a Patient with Single Ventricle Physiology and a Bidirectional Glenn Shunt. Pediatr Cardiol 28, 314–316 (2007). https://doi.org/10.1007/s00246-007-0037-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00246-007-0037-4